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What’s already known about this topic? 
 CDCP1 is expressed in human skin 
 CDCP1 is implicated in cancer metastasis 
 
What does this study add? 
 CDCP1 is localised to the cell-cell contacts of stratum basale keratinocytes during 
epidermogenesis. 
 CDCP1 is involved in keratinocyte chemotactic cell migration. 
 
  
Abbreviations  
 
CDCP1  - CUB Domain Containing Protein 1 
DAB   - 3,3-diaminobenzidine 
DED-HSE  - De-epidermised Dermis Human Skin Equivalent 
DMEM  - Dulbecco’s Modified Eagle Medium 
IHC   - Immunohistochemistry 
FCS  - Fetal calf serum 
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Summary    
   
Background:  
Epidermogenesis and epidermal wound healing are tightly regulated processes during which 
keratinocytes must migrate, proliferate and differentiate. Cell to cell adhesion is crucial to the 
initiation and regulation of these processes. CUB domain containing protein 1 (CDCP1) is a 
transmembrane glycoprotein that is differentially tyrosine phosphorylated during changes in 
cell adhesion and survival signalling and is expressed by keratinocytes in native human skin, 
as well as in primary cultures. 
 
Objectives: To investigate the expression of CDCP1 during epidermogenesis and its role in 
keratinocyte migration. 
 
Methods: We examined both human skin tissue and an in vitro three-dimensional human skin 
equivalent model to examine the expression of CDCP1 during epidermogenesis. To examine 
the role of CDCP1 in keratinocyte migration we used a function blocking anti-CDCP1 
antibody and a real-time Transwell™ cell migration assay.   
 
Results: Immunohistochemical analysis indicated that in native human skin CDCP1 is 
expressed in the stratum basale and stratum spinosum.  In contrast, during epidermogenesis in 
a 3-dimensional human skin equivalent model CDCP1 was expressed only in the stratum 
basale, with localization restricted to the cell-cell membrane.  No expression was detected in 
basal keratinocytes that were in contact with the basement membrane.  Further, an anti-
CDCP1 function blocking antibody was shown to disrupt keratinocyte chemotactic migration 
in vitro.  
 
Conclusions: These findings delineate the expression of CDCP1 in human epidermal 
keratinocytes during epidermogenesis and demonstrate that CDCP1 is involved in 
keratinocyte migration.  
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Introduction      
Chronic wounds, defined as wounds that do not heal within three months, result from 
increasing age, repeated trauma or an underlying co-morbidities, such as diabetes 1 or 
peripheral vascular disease 2. Chronic wound care and its treatment is reported to cost around 
3% of the total health care expenditure in developed countries 3. This equates to $25 billion 
spent annually on chronic wound treatments in the United States with 6.5 million people 
affected 4.  Expectations are that this burden will increase due to the aging population of the 
world and a surge in associated underlying medical conditions 5.   
 
Wound healing results in rapid closure of the wound site, with functional and aesthetic scar 
tissue 6. At the macroscopic level there are three phases of wound healing: inflammation, 
tissue formation, and tissue remodelling 6. The second and third phases require the migration 
and proliferation of keratinocytes to cover the denuded dermal surface. Despite the essential 
role of keratinocytes in skin the molecular mechanisms regulating these cells during wound 
healing and epidermogenesis are only now beginning to be defined 7. This is confounded by 
the lack of animal models that accurately mimic human skin epidermogenesis and wound 
healing.  To overcome this deficit, we have previously developed an ex vivo skin model 
composed of de-epidermised dermis and passage 1 keratinocytes (DED-HSE) 8 that permits 
comparative studies of human epidermogenesis 9, wound/burn healing 10, 11, hyperbaric 
oxygen treatment 12 and application of topical agents to the skin13, 14.   We are also able to 
validate novel keratinocyte culture methods 15, 16.  In this model system, the morphology of 
the de novo epidermis is comparable between native skin and the DED-HSE 8, 10. 
 
CUB domain containing protein 1 (CDCP1) is a ~135 kDa cell surface glycoprotein 17, 18 that 
is expressed by human keratinocytes in intact skin 19 and in primary cultures 20, 21. CDCP1, 
also known as SIMA13517, Trask22 and Gp140 20, 23, contains 3 CUB-like domains 17, 19, 22, 24, 
25 and is required for cancer cell migration in-vitro 26 and cancer dissemination in vivo 
through mechanisms in which CDCP1 protects the cancer cell against apoptosis 27-29.  
Interestingly, several recent reports have demonstrated that CDCP1 interacts with a number of 
proteins involved in skin repair, including the serine proteases plasmin 20 and matriptase 22, 
the tetraspanin CD9 30 and the cell adhesion proteins syndecan I and IV 22 and N- and P-
cadherin 22. In this report we have examined the expression of CDCP1 in native human skin 
and during epidermogenesis using an ex vivo DED-HSE model. Our data indicate that CDCP1 
is involved in keratinocyte cell migration and has a tightly regulated pattern of expression 
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during epidermogenesis where it is localised to the cell-cell membrane in the stratum basale, 
with no expression detected in basal keratinocytes in contact with the basement membrane. 
 
Materials and Methods    
Antibodies – Rabbit anti-CDCP1 antibody #4115 was purchased from Cell Signalling 
Technologies (Denvers, MA) while the monoclonal anti-CDCP1 function blocking antibody 
41-2 was used as described previously 17, 29, 31, 32. 
 
Skin Samples – Skin samples were obtained from adult individuals undergoing elective 
surgery (abdominoplasties or breast reductions) which resulted in a surgical discard. The 
tissue was obtained with informed patient consent, institutional ethical approval (QUT HREC 
# 3865H) and in accordance with the Helsinki declaration.  Separate skin samples were 
utilised for the native skin IHC, generation of the DED-HSE model and cell migration 
experiments. 
 
Isolation of Primary keratinocytes - Primary keratinocytes were isolated from surgical 
samples as described previously 8, 33. Briefly, the epidermis was separated from the dermis by 
incubation in 0.125% trypsin at 4 C overnight. The dermal/epidermal junction was gently 
scraped to remove cells which were collected by centrifugation at 106 x g for 5 minutes. 
Isolated keratinocytes were seeded at a density of 1 x 106 cells/T80 flask onto irradiated (two 
doses of 25 Gy, Australian Red Cross Blood Service, Brisbane, Australia) murine fibroblasts 
3T3 cells (ATCC, Manassas, VA) and cultured in Green’s medium 34 containing DMEM 
(Invitrogen) and HAMS-F12 (Invitrogen) in a 3:1 ratio supplemented with 2 mM L-
Glutamine (Invitrogen), 1000 IU/mL penicillin/streptomycin (Invitrogen), 0.01% (v/v) non-
essential amino acids (Invitrogen), 0.2 µM triiodothyronine (Sigma-Aldrich, Castle Hill, 
NSW, AUS), 180 µM adenine (Sigma-Aldrich), 0.1 µg/mL cholera toxin (Sigma-Aldrich), 
0.4 µg/mL hydrocortisone (Sigma-Aldrich), 5 µg/mL transferrin (Sigma-Aldrich), 10% fetal 
calf serum (FCS; Hyclone), 10 ng/mL EGF (Invitrogen) and 1 µg/mL insulin (Sigma-Aldrich) 
as described previously 8, 33. 
 
Generation of the DED-HSE epidermogenesis model - The DED-HSE model was generated 
as described previously 8. Sterile stainless-steel rings with an internal diameter of 9 mm were 
placed on the papillary side of each 1.4 cm2 DED piece. Keratinocytes (2 x 104) in 200 µl 
(passage 1) were transferred into the rings and incubated for 2 days in Full Greens media at 
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5% CO2 and 37 °C. The rings were removed and the DED-HSEs were lifted to the air:liquid 
interface to allow for epidermal development. The DED-HSEs were cultured in Full Greens 
media at the air:liquid interface for 0, 3, 5 and 9 days. Samples were then fixed in formalin 
and paraffin embedded for subsequent immunohistochemical analysis.  
 
Immunohistochemistry - Sections (5 µm) from formalin fixed and paraffin embedded human 
skin samples and the DED-HSE model were cut and dried onto SuperFrost Plus slides (HD 
Scientific, Willawong, QLD, Australia) at 55 °C overnight. Sections were de-waxed in 
Xylene followed by rehydration in a graded ethanol series. Antigen retrieval was performed in 
sodium citrate buffer, pH 6.0 at 94 °C for 4 minutes using a decloaking chamber (Biocare 
Medical, USA). Following antigen retrieval, the slides were washed twice in PBS for 2 
minutes and manual immunostaining was performed using the MACH 4™ Universal HRP 
Polymer Kit (Biocare Medical). Briefly, endogenous peroxidase activity was quenched using 
Peroxidazed 1™ (Biocare Medical) and non-specific binding sites were blocked with 
Background SNIPER™ (Biocare Medical), a universal blocking buffer, prior to washes in tap 
water, doubly distilled H2O and finally PBS. Primary antibodies against CDCP1 (#4115; 
1:100) 26 were diluted in Da Vinci Green Diluent™ (Biocare Medical), and incubated on the 
sections for 60 minutes at 37 °C. Sections were then washed three times for 5 minutes with 
PBS/0.1% Tween 20. Sections were incubated with a HRP-conjugated anti-rabbit secondary 
antibody (BD Biosciences, Australia) for 15 minutes at room temperature, before being 
washed three times for 5 minutes in PBS/0.1% Tween 20. Slides were then washed in PBS 
prior to incubation with horse radish peroxidise (HRP) polymer. Peroxidase activity was 
detected using 3,3-diaminobenzidine (DAB, Biocare Medical), resulting in formation of a 
brown pigment. Sections were counterstained with Hematoxylin-G1 (HD Scientific) for 3 
minutes, dehydrated and mounted with coverslips under PERTEX mounting medium (HD 
Scientific). Photographs of the slides were taken on an Olympus BX41 microscope with a 
microscope-mounted Nikon Coolpix 4500 digital camera (MicroPublisher 3.3 RTV, 
Olympus, Q-Imaging).  
 
Real-time measurement of cell migration - Keratinocyte migration was measured in real time 
using an xCELLigence system and CIM-cell migration plates (Roche Diagnostics, Mannheim, 
Germany) as described previously 35, 36. Briefly, primary human keratinocytes (passage 1) 
from 3 individuals were serum starved for 4 hours before 5 x 104 cells were seeded into the 
upper chamber of the CIM plate in serum-free medium ± 20 µg/ml of the anti-CDCP1 
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blocking antibody 41-2. The lower chamber contained serum-free growth medium 
supplemented with 2.5% FCS.  The migration of keratinocytes was monitored by 
measurements of changes to the impedance signal across the membrane, as a result of cells 
that had migrated to the underside of the wells. Measurements were taken every 15 minutes 
for 24 hours at 37 °C and 5% CO2. Data acquisition and analysis of cell migration rate were 
performed using the RTCA software supplied with the xCELLigence system (version 1.2, 
Roche Diagnostics).   
 
Results     
 
CDCP1 is localised to the epidermal layer of native human skin.  
CDCP1 has previously been reported to be expressed by primary keratinocytes grown in two 
dimensional culture systems 19, 20 and by keratinocytes in native skin 19.  As analysis of 
CDCP1 in biopsied native human skin was reported previously for only one sample 19, we 
performed immunohistochemical analysis of CDCP1 expression in native skin from the 
surgical discards of 6 individuals undergoing elective surgery. In all samples examined, 
CDCP1 was expressed by keratinocytes in the stratum basale and the stratum spinosum (Fig. 
1, a – f). There was no expression of CDCP1 in the stratum granulosum or the stratum 
corneum. The expression of CDCP1 was cytoplasmic or membrane-associated, with no 
nuclear expression detected. Higher magnification images highlight the membrane staining of 
keratinocytes in the stratum basale (Fig. 1, g-i). Some dermal fibroblast populations were also 
positive for CDCP1 expression. Negative control sections, without primary antibody, were 
free of non-specific staining (data not shown). 
 
CDCP1 expression is restricted to stratum basale keratinocytes during epidermogenesis. 
Epidermogenesis requires the formation of a new epidermal layer, involving keratinocyte 
proliferation, migration and differentiation 37.  To examine the expression of CDCP1 during 
epidermogenesis we utilised our DED-HSE model as described previously 8, 33.  Primary 
keratinocytes (passage 1) which had been cultured for 7 days were seeded onto a de-
epidermised dermis (DED) and cultured for an additional two days. The DED-HSE was then 
raised to the air-liquid interface (day 0) and cultured for up to nine days to monitor 
epidermogenesis. At days 3, 5 and 9, the DED-HSE samples were fixed in formalin, 
embedded in paraffin and immunohistochemical analysis was performed to examine CDCP1 
expression during epidermogenesis. To account for variability among human dermal and 
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epidermal tissue samples, we constructed DED-HSE systems using skin from three different 
individuals. 
 
At day 0 (48 hours after addition of keratinocytes to the DED) CDCP1 expression was 
apparent in the single cell epidermal layer present in each sample (Fig. 2). After three days of 
epidermal growth at the air-liquid interface, CDCP1 was clearly expressed in the stratum 
basale with some diffuse staining apparent in the stratum spinosum (Fig. 2). Higher 
magnification images from day 3 show that expression of CDCP1 in the stratum basale was 
localised to cell – cell contacts, with no apparent expression where keratinocytes were in 
contact with the basement membrane (Fig. 3a). As epidermogenesis proceeded through days 5 
and 9, there was a visible thickening of the stratum corneum, indicating that the DED-HSE 
model undergoes similar keratinocyte differentiation as observed in native skin. During days 
5 and 9, CDCP1 was localised to the stratum basale, with little expression in the stratum 
spinosum and no detectable expression in the stratum granulosum or stratum corneum (Fig. 
2). Higher magnification images from days 5 and 9 show that CDCP1 expression was found 
predominately on the cell – cell contacts with very low to no detectable expression on the cell 
- basement membrane contacts (Fig. 3b-c).  It was interesting to note that a keratinocyte in the 
stratum basale in late anaphase (following DNA division) was visible and despite very 
recently undergoing DNA replication, retained membrane bound CDCP1 expression (Fig. 
3d). 
 
Inhibition of CDCP1 reduces keratinocyte chemotactic cell migration in-vitro. 
Keratinocyte migration is thought to be initiated from the stratum basale of the epidermis 
during epidermogenesis 37. The restricted pattern of CDCP1 expression to this location in the 
developing DED-HSE suggests that CDCP1 may be involved in the keratinocyte migration 
essential for epidermogenesis. To begin to address this possibility we examined the effect of 
an anti-CDCP1 function blocking antibody, 41-2 27, 29, on primary keratinocyte chemotactic 
migration using a real-time cell-migration monitoring system. The 41-2 antibody has been 
shown to inhibit dissemination in animal models of metastasis of epithelial cancer derived 
cells endogenously and ectopically expressing CDCP1 28, 29. While its impact on metastasis of 
these cell lines has been defined as requiring its specific binding to CDCP1 28,  29, the effect of 
this antibody on migrating primary keratinocytes are currently unknown. In these experiments 
FCS supplemented media was used as chemoattractant to stimulate migration of passage 1, 
serum-starved keratinocytes and migration was monitored every 15 minutes for 24 hours. We 
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first assessed the ability of four different FCS concentrations (1.25%, 2.5%, 5% and 10%) to 
stimulate keratinocyte migration, demonstrating that migration increases in response to 
increasing serum concentration and that robust movement of these cells was achieved at FCS 
levels as low as 2.5% (Fig 4a). Accordingly, the inhibitory effect on keratinocyte migration of 
targeting CDCP1 with antibody 41-2 was assessed at a concentration of 2.5% FCS. As shown 
in 4b-d, this antibody markedly inhibited chemotactic migration of primary keratinocytes 
isolated from three different individuals. Quantitative analysis of the linear phase of cell 
migration utilising the slope function in the xCELLigence DP software demonstrated that 41-
2 reduced keratinocyte migration to 50% (Fig. 4b), 64% (Fig. 4c) and 68% (Fig. 4d) of 
untreated primary keratinocytes. Importantly, in control experiments the same concentration 
of isotype matched mouse IgG had no impact on migration of primary keratinocytes induced 
by 2.5% FCS (Fig. 4e). These data suggest that CDCP1 is involved in keratinocyte 
chemotactic cell migration in vitro.   
 
Discussion  
Controlled keratinocyte cell migration, proliferation and differentiation are essential for rapid 
and complete epidermal regeneration during wound healing 7. The underlying mechanisms 
involved with these processes are poorly defined. The ability to understand and manipulate 
these mechanisms offers the potential to improve wound healing and skin repair. CDCP1 is a 
cell surface glycoprotein that has been shown to be expressed by primary epidermal 
keratinocytes 19-21 and by keratinocytes, as evidenced previously, in a single human skin 
sample 19.  It is also required for the dissemination of cancer cells in vitro 19, 26 and in animal 
models of metastasis 29, 38, 39. Here we have examined the expression of CDCP1 in skin from 6 
individuals and also in an in vitro model of human skin epidermogenesis. As our data indicate 
that CDCP1 is differentially expressed during epidermogenesis, we also examined the effect 
of an anti-CDCP1 function blocking antibody on primary keratinocyte migration.  
 
Our results show that CDCP1 is localised to the stratum basale and stratum spinosum in 
native human skin (Fig. 1).  Interestingly, in our in vitro model of epidermogenesis, CDCP1 
was almost exclusively restricted to stratum basale keratinocytes and in these cells it was 
present in lateral and apical cell - cell contacts but was absent from cell contacts with the 
basement membrane (Fig. 2 and 3). This observation is consistent with the findings of Alvares 
et al. who observed the same localisation of CDCP1 in quiescent epidermis from a single 
individual 19. Epidermogenesis is a crucial step in skin regeneration and wound healing 
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resulting in the formation of a new epidermal layer 37. An important process in 
epidermogeneis is the constant shedding and sloughing off of the stratum corneum at the 
cellular surface, which stimulates the process of basal cell proliferation and thus epidermal 
renewal 40. The restricted location of CDCP1 to the stratum basale indicates its possible 
involvement in the regulation of the cell migration necessary for epidermal renewal.   
 
A real-time cell migration assay was used to investigate whether CDCP1 is involved in 
keratinocyte migration. In the presence of the function-blocking anti-CDCP1 antibody 41-2, 
keratinocyte migration was decreased by up to half when 2.5% serum supplemented Greens 
media was used as a chemoattractant (Fig. 4). These data contrast somewhat with the 
observation of Deryugina et al. who demonstrated that while in vitro migration of cervical 
cancer-derived HeLa cells stably expressing CDCP1 (HeLa-CDCP1) was unaffected by 41-2, 
this antibody substantially reduced in vivo dissemination of HeLa-CDCP1 cells 29. Thus, it 
appears likely that both the ability of the 41-2 antibody to disrupt cell motility and the role of 
CDCP1 in this process are context dependent. This possibility is supported by contrasting 
results from our analysis of keratinocytes and a recent study examining the mechanism by 
which antibody 41-2 inhibits CDCP1-mediated cancer cell line dissemination in chicken 
embryo and mouse models of metastasis. Whereas Casar and co-workers 28 recently 
demonstrated that in these in vivo models proteolytic cleavage of CDCP1 is required to 
promote cell survival during transit of cancer cells across endothelial cell layers, we did not 
observe changes in proteolysis of CDCP1 in the in-vitro culture of keratinocyte cell 
populations (data not shown). Accordingly, we speculate that the role of CDCP1 in 
keratinocyte migration is independent of its proteolysis and we are currently exploring the 
mechanism by which this protein is involved in movement of these cells. 
 
The expression and localisation of CDCP1 during epidermogenesis and the ability of an 
antibody targeting this protein to reduce in vitro migration of keratinocytes suggests that 
CDCP1 may have a role in vivo during processes required for skin repair, for example during 
keratinocyte migration into the wound bed or towards the epidermal surface as part of the skin 
regeneration 41, 42.  Thus, based on the restricted localisation of CDCP1 to the stratum basale 
keratinocytes, those cells proposed to hold the regenerative capacity for the skin 37,  this 
protein may prove to be involved in epidermal regeneration potential or a target for re-
initialisation of the migration essential for epidermal wound repair and skin regeneration. 
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Figure Legends 
 
Fig 1. CDCP1 is localised to the stratum basale and stratum spinosum in native human 
skin. Immunohistochemical analysis of CDCP1 expression in native skin from 6 individuals 
(a-f). The presence of the CDCP1 antigen is represented by brown immunoreactivity and all 
nuclei have been counterstained blue with haematoxylin.  The ‘SB’ indicates the stratum 
basale layer of the epidermis in panel (f). Enlarged view of sections from the stratum basale 
and stratum spinosum from native skin (g, h, i). The black scale bar represents 100 µm in 
panels (a-f), whereas it represents 20 µm in panels (g-i). 
 
Fig 2. CDCP1 is localized to the stratum basale in a DED-HSE model of 
epidermogenesis. Immunohistochemical analysis of CDCP1 expression of the DED-HSE 
undergoing epidermogenesis on days 0, 3, 5 and 9 was performed. Keratinocytes from three 
individuals where seeded onto the DED and the formation and stratification of the epidermal 
layer was monitored histologically. The presence of the CDCP1 antigen is indicated by brown 
immunoreactivity and all nuclei have been counterstained blue with haematoxylin. The ‘SB’ 
in the bottom right corner indicates the stratum basale layer of the epidermis and the black 
scale bar represents 100 µm. 
 
Fig 3. CDCP1 is localized to the cell-cell contacts of stratum basale keratinocytes in a 
DED-HSE model of epidermogenesis. Enlarged view of selected sections from days 3 (a), 5 
(b and d) and 9 (c) of epidermogenesis. Brown staining indicates CDCP1 expression.  All 
images are enlargements from those presented in Fig. 2 and the scale bar represents 20 µm. 
The black arrow indicates the dividing cell.  
 
Fig 4. Antibody targeting of CDCP1 reduces keratinocyte chemotactic cell migration in-
vitro. Keratinocyte migration from an upper chamber containing cells to a lower chamber 
containing FCS as chemoattractant was monitored in real time by following changes in 
impedance in an electrode located on the underside of a Transwell™ using the xCELLigence 
DP system and CIM-plates. Passage 1 primary human keratinocytes (5 x 104) were serum 
starved for 4 hours then seeded into the upper chamber and cell migration was monitored 
every 15 minutes for 24 hours. (a) Effect of increasing FCS concentration on keratinocyte 
migration. Black - 1.25% FCS; Blue - 2.5% FCS; Red - 5% FCS; Green - 10% FCS; Average 
of quadruplicate wells are shown +/- SEM. (b-d) Keratinocytes from 3 individuals were 
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seeded in serum-free media alone (red) or serum-free media supplemented with 20 µg/ml 
anti-CDCP1 function blocking antibody (green). The lower chamber contained 2.5% FCS 
supplemented media as a chemoattractant. The rate of cell migration was quantified by 
measuring the slope of each curve during the linear phase (indicated by the vertical lines) 
using the system software. Real time impedance measurements are presented as individual 
traces of duplicate wells, except for panel (c) control where only one measurement is 
displayed. (e) Cells were seeded in the presence of serum-free media (black) or serum-free 
media containing 20 µg/ml isotype matched mouse IgG (red). The lower chamber contained 
2.5% FCS supplemented Greens media. The average of quadruplicate wells are shown +/- 
SEM. 
 
 
